PARP inhibitors like Lynparza from Merck and AstraZeneca have been effective in some patients with ovarian and breast cancers, but many develop resistance to the drugs, and some people don’t respond ...
Takeda has doubled down on KSQ Therapeutics, handing over “double-digit millions of dollars” on day one and committing up to $510 million on the back end to research and validate novel tumor-intrinsic ...
LEXINGTON, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- KSQ Therapeutics, Inc. (KSQ), a clinical-stage biotechnology company developing novel treatments for solid tumors, including engineered ...
KSQ-004EX is a CRISPR/Cas9 engineered eTIL therapy targeting SOCS1 and Regnase-1 genes in solid tumors. The phase 1/2 trial evaluates safety, tolerability, and antitumor activity in advanced solid ...
LEXINGTON, Mass., June 12, 2024 (GLOBE NEWSWIRE) -- KSQ Therapeutics, Inc. (KSQ), a clinical-stage biotechnology company developing treatments for solid tumors, today announced the first patient dosed ...
– Proprietary CRISPRomics™ Drug Discovery Engine Pinpoints the Best Therapeutic Nodes of Diseases; Product Insights Being Translated into Drug Candidates – CAMBRIDGE, Mass.--(BUSINESS WIRE)--KSQ ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--KSQ Therapeutics today announced the appointment of Douglas Pagán as Chief Financial Officer. Mr. Pagán brings more than 25 years of financial and operational ...
KSQ Architects, PC announced today the hiring of three new staff members. George Pritchard has joined the firm as Interior Design Manager. Prior to joining KSQ, Pritchard managed the development and ...
Thompson Construction filed a construction defect lawsuit against KSQ Design and six other defendants on Jan. 15 in Oklahoma District Court for Tulsa County over water damage at Oral Roberts ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback